Expert Consensus on Targeted Therapy of NSCLC with MET Exon 14 Skipping Mutation. (English)
In: Chinese Journal of Lung Cancer, Jg. 26 (2023-06-01), Heft 6, S. 416-428
Online
academicJournal
Zugriff:
The mesenchymal-epithelial transition factor (MET) exon 14 skipping mutation is mainly caused by the loss of c-Cbl tyrosine binding site. This mutation could result in a decrease in the degradation rate of proteasome-mediated MET proteins, trigger continuous activation of downstream pathways, and ultimately lead to tumorigenesis. The incidence of MET exon 14 skipping mutation in patients with non-small cell lung cancer (NSCLC) is 0.9% to 4.0%. Patients with advanced NSCLC are recommended to test MET exon 14 skipping mutations who may benefit from MET inhibitors-targeted therapy. MET inhibitors have a high objective response rate and good safety profiles, which could prolong the survival of NSCLC patients with MET exon 14 skipping mutations. The Lung Cancer Specialty Committee of Chinese Elderly Health Care Association organized multidisciplinary experts to give suggestions on the important issues of clinical aspects for targeted therapy of MET exon 14 skipping mutation in NSCLC according to the clinical practice experiences and evidences based medicine. "Expert Consensus on Targeted Therapy of NSCLC with MET Exon 14 Skipping Mutation" is proposed, aiming to provide standardized guidances for the clinical practice of Chinese physicians. [ABSTRACT FROM AUTHOR]
Copyright of Chinese Journal of Lung Cancer is the property of Chinese Journal of Lung Cancer and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Expert Consensus on Targeted Therapy of NSCLC with MET Exon 14 Skipping Mutation. (English)
|
---|---|
Autor/in / Beteiligte Person: | Jun, CHEN |
Link: | |
Zeitschrift: | Chinese Journal of Lung Cancer, Jg. 26 (2023-06-01), Heft 6, S. 416-428 |
Veröffentlichung: | 2023 |
Medientyp: | academicJournal |
ISSN: | 1009-3419 (print) |
DOI: | 10.3779/j.issn.1009-3419.2023.102.19 |
Schlagwort: |
|
Sonstiges: |
|